Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
Completed
Johns Hopkins University
Phase 2
2004-10-01
Current treatment of tuberculosis (TB) requires patients to take four drugs for 8 weeks and
then two drugs for 4 months. New drug regimens that are shorter and effective against
drug-resistant TB are needed. This study will evaluate whether using the drug moxifloxacin
(MOX) in place of ethambutol (EMB) during the first 8 weeks of treatment will effectively
treat TB.
A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo
Completed
Mylan Bertek Pharmaceuticals
Phase 1
2003-06-01
Nebivolol is one of a class of drugs known as beta-blockers. These drugs are useful in the
treatment of high blood pressure, angina, abnormal heart rhythms and following a heart
attack. The purpose of this study is to explore the potential of nebivolol to cause a certain
type of abnormal heart rhythm, known as QTc prolongation. The potential of nebivolol to cause
this adverse event will be compared to three other drugs: atenolol, a beta-blocker approved
by the FDA; Avelox (moxifloxacin), an anti-biotic approved for use by the FDA which is known
to cause QTc prolongation; and placebo, a drug look-alike that contains no drug. The working
hypothesis was that 20 or 40 mg of nebivolol would not prolong corrected QT intervals
measured during peak nebivolol concentrations (i.e., 2 hours after dosing) on Day 7.
Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration
Completed
Medical University of Vienna
Phase 4
2006-01-01
Penetration of cefpirome and moxifloaxacin into abscess fluid of humans will be tested.
Patients with an abscess scheduled for drainage will receive study drugs (single or multiple
dose), pus samples and plasma samples will be collected and analyzed by High pressure liquid
chromatography (HPLC). Pharmacokinetics of the study drugs in pus and plasma will be
determined using a pharmacokinetic model.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
